Technology Assessment
GZP provides objective technology assessment of intellectual property on behalf of individuals, virtual and small firms, venture capitalists, pharmaceutical partners, and other investors. This includes the scientific and technical review of data and product portfolio information, with pragmatic recommendations on the most likely scenarios for regulatory and clinical success.
When evaluating a medical product investment opportunity, sophisticated investors consistently ask four key questions — and GZP provides rigorous, independent answers to each:
Medical Device Services
✵
Question 1:
“Do You Own It?”
- GZP examines the strength of the patent portfolio, coverage, and remaining exclusivity timeline — providing an objective assessment of the investment’s attractiveness and the intellectual property’s defensibility.
✵
Question 2:
“Does It Works?”
- GZP provides a comprehensive review of all available nonclinical pharmacology, toxicology, mechanistic data, CMC information, and prior clinical data — producing a document that objectively evaluates whether the science supports further development.
✵
Question 3:
“Can You Get It Approved?”
- GZP assesses the strength of the regulatory, preclinical, manufacturing, and clinical program — providing a projected development timeline, key milestones, anticipated regulatory roadblocks, and estimated costs through approval.
✵
Question 4:
“Can You Sell It?”
- GZP provides market intelligence — evaluating dosing, route of administration, dosing interval, patient acceptability, and physician adoption — to inform financial planning and investment decisions before significant capital is committed.
Frequently Asked Questions – Technology Assessment
We are preparing for a Series A fundraise. How can GZP help?
GZP can provide technology assessment documentation that gives investors the regulatory and scientific confidence they need, assist with the preparation of financing roadshow materials, support investor presentations, and help articulate a credible, well-structured development plan — addressing the four key investment questions every sophisticated investor asks.
Can GZP assess a product or portfolio we are considering licensing or acquiring?
Yes. GZP performs independent, objective technology assessments that evaluate the scientific data, regulatory feasibility, approval pathway, and commercial viability of assets. These assessments are used by venture capitalists, pharmaceutical partners, and individual IP holders to inform licensing, partnership, or acquisition decisions.
Have additional inquiries?
We are here to help. Let’s engage in a conversation.